Inarigivir soproxil - Spring Bank Pharmaceuticals

Drug Profile

Inarigivir soproxil - Spring Bank Pharmaceuticals

Alternative Names: GS 9992; Inarigivir; SB-9200

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Spring Bank Pharmaceuticals
  • Developer Gilead Sciences; National Institutes of Health (USA); Spring Bank Pharmaceuticals
  • Class Antivirals; Nucleotides; Small molecules
  • Mechanism of Action DDX58 protein stimulants; NOD2 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • Phase II Hepatitis B
  • Phase I Hepatitis C
  • Preclinical Norovirus infections; Respiratory syncytial virus infections
  • Research Dengue; Japanese encephalitis; West Nile virus infections
  • Suspended Hepatitis D; HIV infections

Most Recent Events

  • 12 Apr 2018 Spring Bank Pharmaceuticals plans a phase I trial for drug interaction potentiation in healthy participants in Netherlands (NCT03493698)
  • 14 Mar 2018 Updated efficacy data from the phase II ACHIEVE trial in Hepatitis B released by Spring Bank Pharmaceuticals
  • 14 Mar 2018 Spring Bank plans to initiate Part B of the phase II ACHIEVE trial in Hepatitis B in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top